Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal-Reference-Cited by-同舟云学术

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Published:2019-03-21 Issue:10 Volume:37 Page:1195-1207
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Grimm Sabine E.^ORCID,Fayter Debra,Ramaekers Bram L. T.,Petersohn Svenja,Riemsma Rob,Armstrong Nigel,Pouwels Xavier,Witlox Willem,Noake Caro,Worthy Gillian,Kleijnen Jos,Joore Manuela A.

Funder

NIHR

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-019-00792-7.pdf

Reference34 articles.

1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013. http://publications.nice.org.uk/pmg9 . Accessed 25 Oct 2017.

2. Fayter D, Grimm S, Ramaekers B, Petersohn S, Riemsma R, Armstrong N, et al. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd; 2017. https://www.nice.org.uk/guidance/ta540/documents/committee-papers . Accessed 22 Nov 2018.

3. National Institute for Health and Care Excellence. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: NICE technology appraisal guidance 540. London: NICE; 2018. https://www.nice.org.uk/guidance/ta540 . Accessed 22 Nov 2018.

4. Merck Sharp & Dohme. Pembrolizumab for treating relapsed or refractory classical Hodgkin’s Lymphoma [ID: 1062]: Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA). Sept 2017. https://www.nice.org.uk/guidance/ta540/documents/committee-papers . Accessed 14 Sep 2017.

5. Cancer Research UK. Hodgkin lymphoma: types. 2014. http://www.cancerresearchuk.org/about-cancer/hodgkin-lymphoma/types . Accessed 5 Oct 2017.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of level of documentation on the accessibility and affordability of new drugs in Norway;Frontiers in Pharmacology;2024-02-14

2. Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report;Cureus;2023-10-13

3. A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma;Expert Review of Hematology;2022-07-03

4. Monoclonal antibodies used for the management of hemataological disorders;Expert Review of Hematology;2022-05-04

5. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal;PharmacoEconomics;2020-11-04